MA55131B1 - Nouveaux composés hétérocycliques - Google Patents

Nouveaux composés hétérocycliques

Info

Publication number
MA55131B1
MA55131B1 MA55131A MA55131A MA55131B1 MA 55131 B1 MA55131 B1 MA 55131B1 MA 55131 A MA55131 A MA 55131A MA 55131 A MA55131 A MA 55131A MA 55131 B1 MA55131 B1 MA 55131B1
Authority
MA
Morocco
Prior art keywords
heterocyclic compounds
new heterocyclic
compounds
methods
new
Prior art date
Application number
MA55131A
Other languages
English (en)
Other versions
MA55131A (fr
Inventor
Bernd Kuhn
Zbinden Katrin Groebke
Fionn O`Hara
Carsten Kroll
Uwe Grether
Didier Rombach
Hans Richter
Benoit Hornsperger
Marius Daniel Rinaldo Lutz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA55131A publication Critical patent/MA55131A/fr
Publication of MA55131B1 publication Critical patent/MA55131B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés hétérocycliques de formule générale (i), dans laquelle a, b, l, x, r1, r2, r3 et r4 sont tels que décrits dans la description, des compositions comprenant les composés, des procédés de fabrication desdits composés et des procédés d'utilisation de ceux-ci.
MA55131A 2018-11-22 2019-11-20 Nouveaux composés hétérocycliques MA55131B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18207725 2018-11-22
PCT/EP2019/081870 WO2020104494A1 (fr) 2018-11-22 2019-11-20 Nouveaux composés hétérocycliques

Publications (2)

Publication Number Publication Date
MA55131A MA55131A (fr) 2022-03-02
MA55131B1 true MA55131B1 (fr) 2023-10-31

Family

ID=64453331

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55131A MA55131B1 (fr) 2018-11-22 2019-11-20 Nouveaux composés hétérocycliques

Country Status (31)

Country Link
US (1) US12577257B2 (fr)
EP (1) EP3883936B1 (fr)
JP (1) JP7444882B2 (fr)
KR (1) KR102913813B1 (fr)
CN (1) CN113166170A (fr)
AR (1) AR117139A1 (fr)
AU (1) AU2019383500B2 (fr)
BR (1) BR112021009348A2 (fr)
CA (1) CA3119506A1 (fr)
CL (1) CL2021001330A1 (fr)
CO (1) CO2021007056A2 (fr)
CR (1) CR20210247A (fr)
DK (1) DK3883936T3 (fr)
ES (1) ES2955037T3 (fr)
FI (1) FI3883936T3 (fr)
HR (1) HRP20231083T1 (fr)
HU (1) HUE062913T2 (fr)
IL (1) IL283333B2 (fr)
LT (1) LT3883936T (fr)
MA (1) MA55131B1 (fr)
MX (1) MX2021005714A (fr)
PE (1) PE20211870A1 (fr)
PH (1) PH12021551167A1 (fr)
PL (1) PL3883936T3 (fr)
PT (1) PT3883936T (fr)
RS (1) RS64579B1 (fr)
SG (1) SG11202104206SA (fr)
SI (1) SI3883936T1 (fr)
TW (1) TWI825227B (fr)
UA (1) UA128505C2 (fr)
WO (1) WO2020104494A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
WO2019105915A1 (fr) 2017-11-28 2019-06-06 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques
WO2019134985A1 (fr) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines en tant qu'inhibiteurs de magl
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
CR20230115A (es) 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos
EP4215526A4 (fr) * 2020-09-18 2024-10-16 Shanghai Pharmaceuticals Holding Co., Ltd. Composé carbonyle hétérocyclique et son utilisation
WO2022165513A1 (fr) 2021-01-29 2022-08-04 Cedilla Therapeutics, Inc. Inhibiteurs de cdk2 et leurs procédés d'utilisation
KR20240000574A (ko) * 2021-04-23 2024-01-02 에프. 호프만-라 로슈 아게 헤테로시클릭 화합물
CA3225439A1 (fr) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Inhibiteurs de cdk2 et leurs procedes d'utilisation
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
WO2023130043A1 (fr) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiteurs de monoacylglycérol lipase et leur utilisation pour le traitement de l'anxiété
US20250170101A1 (en) * 2021-12-29 2025-05-29 Psy Therapeutics, Inc. Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain and related conditions
JP2025504522A (ja) * 2022-01-25 2025-02-12 エフ． ホフマン－ラ ロシュ アーゲー 新規の複素環式化合物
JP2025525350A (ja) * 2022-06-24 2025-08-05 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤としての新規複素環－カルボニル－環式化合物
AR130133A1 (es) 2022-08-08 2024-11-06 Hoffmann La Roche Nuevos compuestos heterocíclicos
US20250388592A1 (en) * 2022-08-11 2025-12-25 Remynd N.V. (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders
JP2025530870A (ja) * 2022-09-20 2025-09-17 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ用蛍光プローブ
TW202428574A (zh) * 2022-10-24 2024-07-16 瑞士商赫孚孟拉羅股份公司 新穎雜環化合物
WO2024168426A1 (fr) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Petites molécules utilisées en tant qu'inhibiteurs de monoacylglycérol lipase (magl), compositions et utilisation associées
CN121843953A (zh) 2023-09-28 2026-04-10 豪夫迈·罗氏有限公司 新颖杂环化合物
TW202539671A (zh) 2024-01-19 2025-10-16 瑞士商赫孚孟拉羅股份公司 新穎雜環化合物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214038A (en) 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
EP1896453B1 (fr) 2005-06-20 2009-12-02 Schering Corporation Pipéridines substituées liées à un atome de carbone et leurs dérivés utiles en tant qu antagonistes de l'histamine h3
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
WO2007098418A1 (fr) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Composes ayant une affinite pour le recepteur 5-ht6
WO2007117557A2 (fr) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanols inhibiteurs de rénine
CA2679754C (fr) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Synthese de gamma-carbolines fusionnees a heterocycles substitues
FR2915197B1 (fr) 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
US8394792B2 (en) 2008-03-31 2013-03-12 C&C Research Laboratories Heterocyclic derivatives
CA2741153A1 (fr) 2008-10-29 2010-05-06 F. Hoffmann-La Roche Ag Nouveaux derives d'amides phenyliques ou d'amides pyridyliques et leur utilisation en tant agonistes de gpbar1
JP2012524809A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としての複素芳香族及び芳香族ピペラジニルアゼチジニルアミド類
CA2773182A1 (fr) 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibiteurs de jak
WO2011059118A1 (fr) 2009-11-10 2011-05-19 Kim Hyun Jeen Système de test de perception olfactive
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
WO2013059118A1 (fr) 2011-10-19 2013-04-25 The Trustees Of Columbia University In The City Of New York Compositions catalytiques à base de cyclopropénimine et procédés
EP2785721A1 (fr) 2011-11-30 2014-10-08 Actelion Pharmaceuticals Ltd. Antibiotiques d'octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one 3,7-disubstituée
MY170922A (en) 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
EA029361B1 (ru) 2013-04-16 2018-03-30 Идорсиа Фармасьютиклз Лтд Антибактериальные биароматические производные
WO2016109501A1 (fr) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Composés amides utilisés en tant qu'inhibiteurs de la tryptophane hydroxylase
WO2016158956A1 (fr) 2015-03-30 2016-10-06 武田薬品工業株式会社 Composé hétérocyclique
CN107635986A (zh) 2015-05-13 2018-01-26 赛尔维他股份公司 取代的喹喔啉衍生物
CA2986199C (fr) 2015-05-21 2023-07-18 Glaxosmithkline Intellectual Property Development Limited Derives de benzoimidazole comme inhibiteurs pad4
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
HK1249101A1 (zh) 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
WO2017087863A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2017087858A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
US10610520B2 (en) 2016-03-31 2020-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
MY194647A (en) 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
KR20190022728A (ko) 2016-06-30 2019-03-06 바실리어 파마슈티카 인터내셔널 리미티드 증식 장애의 치료를 위한 미토콘드리아 억제제
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN110709084A (zh) 2017-03-13 2020-01-17 阿比德治疗公司 双重magl和faah抑制剂
MX394645B (es) 2017-06-12 2025-03-21 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina.
JP7189143B2 (ja) 2017-09-29 2022-12-13 武田薬品工業株式会社 複素環化合物
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
WO2019105915A1 (fr) 2017-11-28 2019-06-06 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques
TW201930300A (zh) 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
WO2019134985A1 (fr) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines en tant qu'inhibiteurs de magl
MX2020008894A (es) 2018-03-22 2020-10-12 Hoffmann La Roche Inhibidores de oxazin monoacilglicerol lipasa (magl).
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020035425A1 (fr) 2018-08-13 2020-02-20 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
WO2020207941A1 (fr) 2019-04-09 2020-10-15 F. Hoffmann-La Roche Ag Composés hétérocycliques en tant qu'inhibiteurs de la monoacylglycérol lipase (magl)
JP7669299B2 (ja) 2019-07-03 2025-04-28 エフ． ホフマン－ラ ロシュ アーゲー 複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤
JP7649283B2 (ja) 2019-07-09 2025-03-19 エフ． ホフマン－ラ ロシュ アーゲー 新規複素環化合物
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
JP2022548018A (ja) * 2019-09-12 2022-11-16 エフ．ホフマン－ラ ロシュ アーゲー 放射性標識化合物
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
EP4034239A1 (fr) 2019-09-23 2022-08-03 F. Hoffmann-La Roche AG Composés hétérocycliques
AU2020354414A1 (en) 2019-09-24 2022-02-17 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (MAGL) inhibitors
BR112022003357A2 (pt) 2019-09-24 2022-05-17 Hoffmann La Roche Compostos heterocíclicos
EP4034602A1 (fr) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG Sondes fluorescentes pour la monoacylglycérol lipase (magl)
CN116096723A (zh) 2020-08-26 2023-05-09 豪夫迈·罗氏有限公司 用作magl抑制剂的杂环化合物
CR20230115A (es) 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos
KR20240000574A (ko) 2021-04-23 2024-01-02 에프. 호프만-라 로슈 아게 헤테로시클릭 화합물

Also Published As

Publication number Publication date
US12577257B2 (en) 2026-03-17
HRP20231083T1 (hr) 2023-12-22
IL283333A (en) 2021-07-29
IL283333B1 (en) 2024-04-01
DK3883936T3 (da) 2023-09-18
PE20211870A1 (es) 2021-09-21
LT3883936T (lt) 2023-09-25
TWI825227B (zh) 2023-12-11
JP2022507919A (ja) 2022-01-18
PL3883936T3 (pl) 2023-11-20
CN113166170A (zh) 2021-07-23
UA128505C2 (uk) 2024-07-31
CR20210247A (es) 2021-06-08
MA55131A (fr) 2022-03-02
TW202039513A (zh) 2020-11-01
EP3883936A1 (fr) 2021-09-29
AU2019383500B2 (en) 2025-09-18
FI3883936T3 (fi) 2023-09-05
KR20210094540A (ko) 2021-07-29
PH12021551167A1 (en) 2021-10-25
BR112021009348A2 (pt) 2021-08-10
EP3883936B1 (fr) 2023-07-12
IL283333B2 (en) 2024-08-01
KR102913813B1 (ko) 2026-01-16
SI3883936T1 (sl) 2023-10-30
AR117139A1 (es) 2021-07-14
SG11202104206SA (en) 2021-06-29
AU2019383500A1 (en) 2021-05-27
CA3119506A1 (fr) 2020-05-28
NZ775640A (en) 2024-10-25
US20210387999A1 (en) 2021-12-16
JP7444882B2 (ja) 2024-03-06
CL2021001330A1 (es) 2021-10-29
PT3883936T (pt) 2023-09-04
RS64579B1 (sr) 2023-10-31
MX2021005714A (es) 2021-07-21
HUE062913T2 (hu) 2023-12-28
ES2955037T3 (es) 2023-11-28
WO2020104494A1 (fr) 2020-05-28
CO2021007056A2 (es) 2021-06-10

Similar Documents

Publication Publication Date Title
MA53219B1 (fr) Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MA64323B1 (fr) Inhibiteurs de nlrp3
MA48594B1 (fr) Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA49560B1 (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA63458B1 (fr) Nouveaux dérivés de sulfonamide pyrimidin-2-yl
MA32391B1 (fr) Activateurs de la glucokinase
MA31690B1 (fr) Nouveaux fongicides
HRP20041042A2 (hr) Novi supstituirani derivati sulfamata kao antikonvulzivi
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
HRP20060254A2 (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
ATE433447T1 (de) Pyrimiidinverbindungen
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
MA31597B1 (fr) Nouveaux herbicides
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA31596B1 (fr) Nouveaux herbicides
ATE452882T1 (de) Herstellung von quetiapin
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
PA8663901A1 (es) Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol, su prepararacion y su aplicacion en terapéutica
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств